Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement Platform Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement Platform